CRISPR Therapeutics (CRSP) Metrics: History & Chart

CRISPR Therapeutics AG(CRSP)

Biotechnology · Zug, ZG

$55.43-0.01 (-0.02%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Zug, ZG

393 employees

www.crisprtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Samarth Kulkarni

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-0.47%
30D Total Return	-2.43%
YTD Total Return	+5.72%
1Y Total Return	-16.20%
3Y Total Return	+22.14%
5Y Total Return	-50.18%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+5.72%
2025	+33.23%
2024	-37.12%
2023	+54.00%
2022	-46.36%
2021	-50.51%
2020

CAGR TTM	-16.21%
CAGR 3Y	+6.88%
CAGR 5Y	-13.01%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	22.55
PE Ratio Avg TTM	17.47
PE Ratio Avg 3Y	38.57
Current VS TTM Avg	+29.11%
Current VS 3Y Avg	-41.53%
Current VS 5Y Avg	-41.53%

All Metrics

CRSP Valuation Metrics

CRSP Stock Price Metrics

CRSP Dividend Metrics

CRSP Growth Rate Metrics

CRSP Discounted Cash Flow Metrics

CRSP Returns By Period

CRSP Yearly Returns

CRSP Average Annual Returns By Period (CAGR)

CRSP Revenue Metrics

CRSP PE Ratio Metrics

CRSP PS Ratio Metrics

CRSP PB Ratio Metrics

CRSP Price to Free Cash Flow Ratio Metrics

CRSP Debt to Equity Ratio Metrics

CRSP PEG Ratio Metrics

CRSP FCF Yield

CRSP Earnings Yield

CRSP EBITDA Yield

CRSP OCF Yield

CRSP EV/EBIT Ratio Metrics

CRSP EV/EBITDA Ratio Metrics

CRSP EV/Assets Ratio Metrics

CRSP EV/Sales Ratio Metrics

CRSP Current Ratio Metrics

CRSP Quick Ratio Metrics

CRSP ROIC Metrics

CRSP Return on Assets Metrics

CRSP Return on Equity Metrics

CRSP Net Profit Margin Metrics

CRSP Gross Profit Margin Metrics

CRSP Tax Rate Metrics

PS Ratio	399.55
PS Ratio Avg TTM	711.59
PS Ratio Avg 3Y	63.00
Current VS TTM Avg	-43.85%
Current VS 3Y Avg	+534.22%
Current VS 5Y Avg	+318.26%

PB Ratio	3.06
PB Ratio Avg TTM	2.74
PB Ratio Avg 3Y	2.48
Current VS TTM Avg	+11.70%
Current VS 3Y Avg	+23.33%
Current VS 5Y Avg	+28.84%

PFCF Ratio	15.14
PFCF Ratio Avg TTM	13.18
PFCF Ratio Avg 3Y	68.65
Current VS TTM Avg	+14.91%
Current VS 3Y Avg	-77.95%
Current VS 5Y Avg	-77.95%

Debt/Equity Ratio	0.45
Debt/Equity Ratio Avg TTM	0.28
Debt/Equity Ratio Avg 3Y	0.14
Current VS TTM Avg	+57.46%
Current VS 3Y Avg	+223.42%
Current VS 5Y Avg	+271.93%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	6.60%
FCF Yield Avg TTM	8.07%
FCF Yield Avg 3Y	4.52%
Current VS TTM Avg	-18.18%
Current VS 3Y Avg	+46.13%
Current VS 5Y Avg	+46.13%

Earnings Yield	4.44%
Earnings Yield Avg TTM	6.02%
Earnings Yield Avg 3Y	4.00%
Current VS TTM Avg	-26.25%
Current VS 3Y Avg	+11.00%
Current VS 5Y Avg	+11.00%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	18.68
Ev/Ebit Ratio Avg TTM	13.54
Ev/Ebit Ratio Avg 3Y	18.38
Current VS TTM Avg	+37.92%
Current VS 3Y Avg	+1.61%
Current VS 5Y Avg	+1.61%

Ev/Ebitda Ratio	17.49
Ev/Ebitda Ratio Avg TTM	12.99
Ev/Ebitda Ratio Avg 3Y	35.42
Current VS TTM Avg	+34.68%
Current VS 3Y Avg	-50.62%
Current VS 5Y Avg	-50.62%

Ev/Assets Ratio	2.20
Ev/Assets Ratio Avg TTM	2.14
Ev/Assets Ratio Avg 3Y	2.00
Current VS TTM Avg	+2.86%
Current VS 3Y Avg	+9.81%
Current VS 5Y Avg	+16.28%

Ev/Sales Ratio	436.32
Ev/Sales Ratio Avg TTM	742.86
Ev/Sales Ratio Avg 3Y	62.53
Current VS TTM Avg	-41.26%
Current VS 3Y Avg	+597.74%
Current VS 5Y Avg	+363.73%

Current Ratio	17.85
Current Ratio Avg TTM	16.38
Current Ratio Avg 3Y	16.22
Current VS TTM Avg	+8.97%
Current VS 3Y Avg	+10.02%
Current VS 5Y Avg	+0.40%

Quick Ratio	17.85
Quick Ratio Avg TTM	16.38
Quick Ratio Avg 3Y	16.22
Current VS TTM Avg	+8.97%
Current VS 3Y Avg	+10.02%
Current VS 5Y Avg	+0.40%

ROIC	(21.12%)
ROIC Avg 3Y	(19.82%)
ROIC Avg 5Y	(21.98%)
Current VS 3Y Avg	-6.59%
Current VS 5Y Avg	+3.91%
Current VS 10Y Avg	+7.59%

ROA	(17.02%)
ROA Avg TTM	(5.75%)
ROA Avg 3Y	(4.48%)
Current VS TTM Avg	-196.21%
Current VS 3Y Avg	-279.74%
Current VS 5Y Avg	-247.85%

ROE	(25.83%)
ROE Avg TTM	(28.05%)
ROE Avg 3Y	(20.62%)
Current VS TTM Avg	+7.91%
Current VS 3Y Avg	-25.29%
Current VS 5Y Avg	-33.93%

Net Profit Margin	(3368.72%)
Net Profit Margin Avg TTM	(11959.42%)
Net Profit Margin Avg 3Y	(10580.90%)
Current VS TTM Avg	+71.83%
Current VS 3Y Avg	+68.16%
Current VS 5Y Avg	+67.69%

Gross Profit Margin	(6537.01%)
Gross Pft Margin Avg TTM	(4621.96%)
Gross Pft Margin Avg 3Y	(4083.08%)
Current VS TTM Avg	-41.43%
Current VS 3Y Avg	-60.10%
Current VS 5Y Avg	-25.35%

Tax Rate	0.26%
Tax Rate Avg 3Y	0.40%
Tax Rate Avg 5Y	0.25%
Current VS 3Y Avg	-35.20%
Current VS 5Y Avg	+2.66%
Current VS 10Y Avg	-98.00%